Movement Alert｜CARsgen Therapeutics-B Falls 5.13% in Regular Trading, Strategic Pivot Away from Autologous CAR-T Pipeline Sparks Market Concerns

Market Focus07-07

On July 7, CARsgen Therapeutics-B declined 5.13% in regular trading, trading at HKD 15.19/share, with turnover of HKD 17.54 million.

On the news front, company founder and CEO Li Zonghai recently stated publicly that after successfully developing the world's first solid tumor CAR-T product, the company has decided to cease all new autologous CAR-T pipeline development, shifting its R&D focus entirely toward universal (allogeneic) CAR-T therapies. This strategic pivot raised market concerns over the near-to-medium-term commercialization ceiling of the company's autologous CAR-T business, which currently generates the bulk of its revenue.

At the sector level, the broader biotechnology space was under pressure on the same day, with Remegen down 3.81%, BeiGene down 2.31%, and Akeso down 1.96%, amplifying selling pressure on individual names. The company's flagship autologous product Satri-Cel (targeting Claudin18.2 for gastric cancer) was approved on June 22 as the world's first solid tumor CAR-T therapy, priced at RMB 990,000 per dose with an estimated 200 orders for the year.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1176659568?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-07 11:03","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1176659568","market":"hk","top_or_hot":-1,"title":"Movement Alert｜CARsgen Therapeutics-B Falls 5.13% in Regular Trading, Strategic Pivot Away from Autologous CAR-T Pipeline Sparks Market Concerns","media":"Market Focus","content":"<p><p>On July 7, CARsgen Therapeutics-B declined 5.13% in regular trading, trading at HKD 15.19/share, with turnover of HKD 17.54 million.</p><p>On the news front, company founder and CEO Li Zonghai recently stated publicly that after successfully developing the world's first solid tumor CAR-T product, the company has decided to cease all new autologous CAR-T pipeline development, shifting its R&D focus entirely toward universal (allogeneic) CAR-T therapies. This strategic pivot raised market concerns over the near-to-medium-term commercialization ceiling of the company's autologous CAR-T business, which currently generates the bulk of its revenue.</p><p>At the sector level, the broader biotechnology space was under pressure on the same day, with Remegen down 3.81%, BeiGene down 2.31%, and Akeso down 1.96%, amplifying selling pressure on individual names. The company's flagship autologous product Satri-Cel (targeting Claudin18.2 for gastric cancer) was approved on June 22 as the world's first solid tumor CAR-T therapy, priced at RMB 990,000 per dose with an estimated 200 orders for the year.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜CARsgen Therapeutics-B Falls 5.13% in Regular Trading, Strategic Pivot Away from Autologous CAR-T Pipeline Sparks Market Concerns</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜CARsgen Therapeutics-B Falls 5.13% in Regular Trading, Strategic Pivot Away from Autologous CAR-T Pipeline Sparks Market Concerns\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-07-07 11:03</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On July 7, CARsgen Therapeutics-B declined 5.13% in regular trading, trading at HKD 15.19/share, with turnover of HKD 17.54 million.</p><p>On the news front, company founder and CEO Li Zonghai recently stated publicly that after successfully developing the world's first solid tumor CAR-T product, the company has decided to cease all new autologous CAR-T pipeline development, shifting its R&D focus entirely toward universal (allogeneic) CAR-T therapies. This strategic pivot raised market concerns over the near-to-medium-term commercialization ceiling of the company's autologous CAR-T business, which currently generates the bulk of its revenue.</p><p>At the sector level, the broader biotechnology space was under pressure on the same day, with Remegen down 3.81%, BeiGene down 2.31%, and Akeso down 1.96%, amplifying selling pressure on individual names. The company's flagship autologous product Satri-Cel (targeting Claudin18.2 for gastric cancer) was approved on June 22 as the world's first solid tumor CAR-T therapy, priced at RMB 990,000 per dose with an estimated 200 orders for the year.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02171","symbol_name":"科济药业-B","start_time":0,"source_url":"","article_id":"1176659568","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1176659568","pubTimestamp":1783393421,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On July 7, CARsgen Therapeutics-B declined 5.13% in regular trading, trading at HKD 15.19/share, with turnover of HKD 17.54 million.On the news front, company founder and CEO Li Zonghai recently...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02171":"科济药业-B"},"translate_title":"动向提示|科济生物-B常规交易跌5.13%战略转向自体CAR-T管线引发市场担忧","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02171":1},"content_text":"On July 7, CARsgen Therapeutics-B declined 5.13% in regular trading, trading at HKD 15.19/share, with turnover of HKD 17.54 million.On the news front, company founder and CEO Li Zonghai recently stated publicly that after successfully developing the world's first solid tumor CAR-T product, the company has decided to cease all new autologous CAR-T pipeline development, shifting its R&D focus entirely toward universal (allogeneic) CAR-T therapies. This strategic pivot raised market concerns over the near-to-medium-term commercialization ceiling of the company's autologous CAR-T business, which currently generates the bulk of its revenue.At the sector level, the broader biotechnology space was under pressure on the same day, with Remegen down 3.81%, BeiGene down 2.31%, and Akeso down 1.96%, amplifying selling pressure on individual names. The company's flagship autologous product Satri-Cel (targeting Claudin18.2 for gastric cancer) was approved on June 22 as the world's first solid tumor CAR-T therapy, priced at RMB 990,000 per dose with an estimated 200 orders for the year.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.46.0","shortVersion":"4.46.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1176659568","isCrawlerRequest":true}